Repeated Loss Requires Care, Not a Catalogue of Tests
Pregnancy loss is common, but recurrence changes the clinical and emotional meaning of the experience. After two or more losses, patients often arrive with a long list of possible explanations: chromosomes, blood clotting, immune cells, hormones, the uterus, sperm DNA, infection, stress, or something they may have done.
Some of these questions deserve investigation. Others lead to tests that are poorly standardised, difficult to interpret, or unable to change treatment.
Recurrent pregnancy loss is not the same as infertility and not the same as recurrent implantation failure. Pregnancy has occurred; the clinical question is why it did not continue and what can reasonably improve the next pregnancy pathway.
At Jinemed, investigation begins after the history has been reconstructed and the losses have been defined. The objective is not to produce an abnormal result at any cost. It is to identify findings with a credible relationship to recurrence, provide treatment when evidence supports it, and protect patients from interventions built mainly on uncertainty.
What Counts as Recurrent Pregnancy Loss?
Definitions have changed as early pregnancy testing has become more accessible. Current professional guidance increasingly recognises recurrent pregnancy loss after two or more spontaneous pregnancy losses, while exact definitions may differ between systems and countries.
The record should distinguish:
- Biochemical pregnancy loss after a positive hCG test
- Ultrasound-confirmed intrauterine loss
- Pregnancy of unknown location
- Ectopic pregnancy
- Molar pregnancy
- Loss later in pregnancy
- Termination for a fetal or maternal indication
These outcomes are not biologically or clinically interchangeable. Confirmed ectopic and molar pregnancies, for example, require their own pathways.
Consecutive and non-consecutive losses both matter. A previous live birth does not make recurrent loss unimportant, and secondary recurrent loss may still justify evaluation.
Accurate classification determines which evidence applies.
The First Step Is a Pregnancy Timeline
Before ordering tests, the team should build a chronological record of every pregnancy.
Useful information includes:
- Date and method of conception
- Maternal and paternal ages at the time
- Natural conception, ovulation induction, IUI, or IVF
- Embryo stage and genetic testing where applicable
- First positive pregnancy test and hCG pattern
- Ultrasound findings and gestational age
- Fetal cardiac activity, if observed
- Symptoms and medical treatment
- Pathology or chromosome testing of pregnancy tissue
- Method used to manage the loss
- Complications, infection, or haemorrhage
- Time between pregnancies
The timeline may reveal that events previously called “miscarriages” included different diagnoses. It may also show whether losses occurred at a similar developmental stage or in different circumstances.
Records are especially important for international patients because verbal summaries can change as information passes between hospitals, languages, and years.
Most Early Losses Begin with Embryo Chromosomes
Chromosomal abnormalities in the embryo are a major cause of early miscarriage. Their frequency is strongly influenced by egg age, although chromosome errors can occur at any age.
This does not mean that every recurrent loss is genetic or that a couple has inherited a chromosome problem.
Chromosome analysis of pregnancy tissue can provide information about a specific loss. It may show aneuploidy, a structural imbalance, or no reportable abnormality. The method used, sample quality, maternal-cell contamination, and the possibility of an inconclusive result should be explained.
When tissue testing identifies an unbalanced structural rearrangement, or when the history raises suspicion, parental karyotyping and genetic counselling may be appropriate. Most parental chromosome results will be normal, but a balanced rearrangement can influence recurrence counselling and reproductive options.
Genetic findings should be interpreted with a counsellor or clinician able to explain what the result means for the next pregnancy—not only what it meant for the last one.
Pregnancy-Tissue Testing Has Limits
Testing a miscarriage can answer whether a chromosome abnormality was found in that pregnancy. It cannot explain every loss or guarantee that the next pregnancy will have the same result.
A normal chromosome result does not prove that the uterus, immune system, or sperm caused the loss. It may reflect a genetic condition outside the test’s scope, a placental or developmental problem, a maternal medical factor, or an unexplained event.
Likewise, an aneuploid result may provide a plausible explanation without proving that no other relevant factor exists.
The result should guide the next level of evaluation rather than end or multiply the investigation automatically.
Uterine Anatomy Should Be Evaluated with the Right Method
The uterine cavity and uterine shape may be relevant in recurrent loss. Findings can include a septum, cavity-distorting fibroid, adhesions, polyp, or another congenital or acquired abnormality.
Assessment may use:
- Transvaginal ultrasound
- Three-dimensional ultrasound
- Saline-infusion sonography
- Hysteroscopy
- MRI in selected anatomy
The method should match the question. Three-dimensional ultrasound is particularly helpful when a uterine anomaly is suspected. Hysteroscopy allows direct cavity treatment but does not show the complete external uterine contour.
Surgery is not justified simply because an anatomical variation exists. A uterine septum may be considered for hysteroscopic incision through shared decision-making, with a stronger rationale in recurrent miscarriage than in infertility alone. Fibroids, polyps, and adhesions require location- and evidence-specific decisions.
Correct diagnosis comes before correction.
Antiphospholipid Syndrome Is a Defined, Treatable Condition
Antiphospholipid syndrome is an autoimmune condition associated with pregnancy complications and thrombosis. It is one of the important evidence-based areas of recurrent-loss evaluation.
Diagnosis requires an appropriate clinical history and specified laboratory criteria. A single weakly positive result does not establish the syndrome. Testing must follow recognised antibody definitions and, when required, confirmation over time.
When obstetric antiphospholipid syndrome is diagnosed, aspirin and heparin-based treatment may be considered according to specialist guidance.
This should not be confused with giving anticoagulants to everyone with unexplained recurrent loss.
Blood-thinning treatment has risks, including bleeding and medication burden. It should be linked to a recognised indication rather than used as symbolic protection.
Inherited Thrombophilia Testing Should Not Be Automatic
Patients are often offered large inherited-clotting panels after early miscarriages. The association between common inherited thrombophilias and recurrent early loss is inconsistent, and routine testing does not reliably improve outcomes.
Testing may be relevant when the patient has a personal history of venous thromboembolism or a strong family history suggesting high thrombosis risk. In that setting, the purpose may be maternal risk management as much as miscarriage investigation.
An abnormal thrombophilia result does not automatically prove causation. Treatment should be based on the specific condition, clinical history, pregnancy risk, and specialist assessment.
More clotting tests do not create more certainty when the pre-test probability is low.
Thyroid and Medical Health Require Targeted Review
Preconception assessment should consider thyroid function and established endocrine or medical disease.
Uncontrolled overt thyroid disease, diabetes, hypertension, and other conditions can affect pregnancy health. Treatment should follow recognised medical thresholds rather than fertility-specific targets invented without evidence.
Thyroid antibodies may be associated with pregnancy risk in some populations, but giving thyroid hormone to every euthyroid antibody-positive patient has not consistently improved live birth.
Other tests—such as prolactin, glucose assessment, or evaluation for specific disease—should be guided by symptoms, history, and clinical findings.
The aim is to optimise real medical conditions, not turn normal physiology into a diagnosis.
The Male Partner Is Part of the Pregnancy History
Recurrent loss is often discussed as if it belongs only to the pregnant patient.
The male partner’s age, medical and reproductive history, semen findings, medications, smoking, heat or toxic exposures, and family history may be relevant. A standard semen analysis may be appropriate when fertility evaluation has not been completed.
Sperm DNA-fragmentation testing has been studied in recurrent loss, but methods, thresholds, and treatment implications vary. It may be considered selectively; it should not be presented as a universal explanation or a test that automatically determines whether ICSI, antioxidants, or surgical sperm retrieval will prevent miscarriage.
An abnormal result is useful only if it leads to a proportionate and evidence-supported decision.
Immune Testing Is Where Over-Testing Often Begins
The immune system plays an essential role in pregnancy. That biological truth does not validate every commercial immune panel.
Tests involving natural-killer-cell number or activity, cytokine profiles, HLA matching, Th1/Th2 ratios, and other immune markers may lack standardised methods, validated thresholds, or proof that changing the result improves live birth.
These tests can lead to corticosteroids, intralipid infusions, intravenous immunoglobulin, lymphocyte therapy, or other interventions with cost and potential harm.
Patients should ask:
- Is this test recommended by a current professional guideline?
- Is the laboratory method validated for recurrent loss?
- What result is considered abnormal, and why?
- Does treatment based on that result improve live birth?
- What are the risks?
“Immune cause” should not become the default label for unexplained loss.
Infection Testing Should Follow Clinical Evidence
Routine screening for broad panels of organisms is not supported when there are no symptoms, exposures, or clinical findings.
Chronic endometritis is an area of continuing research. Diagnosis generally requires appropriate endometrial sampling and pathology rather than hysteroscopic appearance alone. Definitions and treatment evidence remain variable.
Testing may be considered in selected patients based on history and local protocols, but repeated antibiotics should not be prescribed simply because a microbiome result differs from a commercial reference range.
Infection treatment should target a recognised infection. Antibiotics are not a general implantation therapy.
Ovarian Reserve Is Not a Miscarriage Diagnosis
AMH and antral follicle count estimate egg quantity and likely response to stimulation. They do not directly measure egg quality and cannot diagnose the cause of a miscarriage.
Low ovarian reserve may coexist with recurrent loss, particularly as reproductive age advances, and fewer eggs may reduce the opportunity to obtain a chromosomally suitable embryo. This is different from saying that low AMH itself caused the losses.
Reserve testing can help plan fertility treatment. It should not be used to create a false causal explanation for pregnancy history.
Age, pregnancy-tissue results, ovarian response, and reproductive goals need to be interpreted together.
PGT-A Is an Option, Not a Universal Cure for Recurrent Loss
Preimplantation genetic testing for aneuploidy can identify embryos reported as euploid, aneuploid, mosaic, or inconclusive before transfer.
For selected patients, it may reduce the transfer of embryos with detected chromosome abnormalities and may change time to pregnancy or miscarriage experience. It does not create normal embryos, correct age-related biology, or guarantee live birth.
Whether PGT-A improves cumulative live birth for every recurrent-loss patient remains uncertain. The pathway also requires IVF, embryo culture, biopsy, freezing, cost, and the possibility that no embryo reaches testing or is reported suitable for transfer.
The decision should consider age, number of expected blastocysts, prior tissue results, time, cost, and the patient’s values.
Using IVF and PGT-A after recurrent loss is a reproductive strategy—not proof that natural conception is unsafe.
Aspirin, Heparin, Progesterone, and Metformin Need Indications
These medicines are frequently used after loss, sometimes before the investigation is complete.
Aspirin and heparin have an established role in defined antiphospholipid syndrome and other specific maternal indications. They are not universal treatments for unexplained recurrent loss.
Progesterone may be considered in selected clinical situations, including particular histories of recurrent loss and early-pregnancy bleeding, depending on applicable guidance. It should not be described as protection against every cause of miscarriage.
Metformin may be indicated for metabolic or fertility aspects of PCOS in selected patients. It has not been shown to prevent every miscarriage in PCOS and should not be continued or started automatically only because a pregnancy test is positive.
A medication can be familiar and still require a reason.
Lifestyle Review Should Support Health, Not Assign Blame
Smoking, alcohol, substance exposure, severe uncontrolled medical risk, and aspects of weight or nutrition may influence pregnancy health. Preconception care should address modifiable risks respectfully and realistically.
This is different from telling a patient that stress, exercise, work, travel, or a particular meal caused recurrent loss.
Psychological distress is common after miscarriage and may affect sleep, relationships, and the ability to continue treatment. Support is part of care, but emotional calm cannot guarantee chromosome-normal conception or prevent every loss.
The patient deserves help without being made responsible for biology outside their control.
Unexplained Does Not Mean Untreatable—or Untested Enough
Even after appropriate evaluation, some recurrent-loss cases remain unexplained.
This result can feel unsatisfactory, but it is more honest than converting weak associations into diagnoses.
Unexplained recurrent loss may still have a reasonable chance of future live birth, influenced strongly by age, number and timing of previous losses, and other clinical factors. Care may include preconception optimisation, early pregnancy contact, appropriate ultrasound, symptom guidance, and emotional support.
The answer to an unexplained result is not necessarily a larger laboratory panel. Sometimes it is a better plan for the next pregnancy.
Early-Pregnancy Care Should Be Written Before Conception
A recurrent-loss consultation should end with a pathway for the next positive test.
The plan may specify:
- Which medications continue or begin
- When beta-hCG testing is useful
- When ultrasound should occur
- Who reviews results
- Which pain or bleeding symptoms require urgent assessment
- How ectopic pregnancy will be excluded
- Whether specialist obstetric input is needed
- What genetic or prenatal testing will be discussed
- How support can be accessed
Surveillance does not prevent every loss, but it reduces uncertainty and delayed care.
Continuity is especially important for international patients whose testing and ultrasound will occur in another country.
A Focused Recurrent-Loss Evaluation
At Jinemed, the investigation can be organised around six questions:
- Were the pregnancies and losses classified correctly?
- Is chromosome information available from pregnancy tissue or the parents?
- Has uterine anatomy been assessed with an appropriate method?
- Is there evidence for antiphospholipid syndrome or another defined medical condition?
- Are male, age-related, and general fertility factors relevant?
- Which finding would actually change treatment or the next-pregnancy plan?
Tests outside this framework may still be appropriate in a specific case, but their indication should be stated.
Investigation Without Over-Testing
Recurrent pregnancy loss deserves more than reassurance. It also deserves more than an indiscriminate search for abnormalities.
At Jinemed, evidence-based care means investigating recognised genetic, anatomical, autoimmune, endocrine, medical, and reproductive factors while explaining the limits of each result.
It means treating antiphospholipid syndrome when diagnosed, correcting relevant uterine pathology, managing established disease, using genetics with counselling, and resisting treatments that have not shown meaningful benefit.
The goal is not to promise that the next pregnancy cannot end in loss.
It is to make sure that correctable factors are addressed, unnecessary treatment is avoided, and the patient enters the next pregnancy with a plan grounded in evidence rather than fear.